DHR Stock Analysis: Buy, Sell, or Hold?
DHR - Danaher Corporation
$183.26
1.74 (0.96%)
▲
5d:
-3.55%
30d:
-13.0%
90d:
-20.43%
BUY
HIGH Confidence
Analysis Updated: Mar 30, 2026 12:00 AM ET
Earnings: Apr 21, 2026
21d
Smart Money Accumulation
DHR is down 4.1% this week, but smart money is accumulating calls. Top strike: $210 2026-05-15 with 9,592 OI. Call ratio: 63% View Scanner →
Strength: 3.4/10
Get Alerted When DHR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: DHR trading at deep discount. Market pricing in -7.2% annual earnings decline, creating value opportunity for patient investors.
✅ BUY SIGNAL: DHR trading at deep discount. Market pricing in -7.2% annual earnings decline, creating value opportunity for patient investors.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$305.46
Based on 6.2% avg growth
INTRINSIC VALUE TODAY
$189.67
3.4% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 24.9x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: DHR is currently trading at $183.26, which is considered oversold relative to its 30-day fair value range of $187.81 to $206.70. From a valuation perspective, the stock is trading at a discount (Forward PE: 19.9) compared to its historical average (24.9). Remarkably, the market is currently pricing in an annual earnings decline of 7.2% over the next few years. This pessimistic expectation contrasts with the company's recent 12.5% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, DHR is in a strong downtrend. The price is currently testing key support at $181.01. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $264.91 (+45.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, DHR is in a strong downtrend. The price is currently testing key support at $181.01. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $264.91 (+45.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$187.81 -
$206.70
Company Quality Score
61/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
79.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 45.9% below Wall St target ($264.91)
Fair Price Analysis
30-Day Fair Range
$187.81 -
$206.70
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$181.01
Resistance Level
$196.75
Current Trend
Strong Downtrend
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
19.93
Wall Street Target
$264.91
(+45.9%)
Revenue Growth (YoY)
4.6%
Earnings Growth (YoY)
12.5%
Profit Margin
14.7%
Valuation Discount vs History
-7.2% cheaper
PE vs Historical
19.9 vs 24.9
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-7.2%
(market-implied from PE analysis)
1-Year Target
$168.45
(-7%)
2-Year Target
$156.32
(-14%)
3-Year Target
$145.07
(-20%)
3-Yr Target (if PE normalizes)
(PE: 20→25)
$181.23
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.4, Growth: 8.3%)
$258.93
(+43%)
Base:
(SPY PE: 19.9, Growth: 8.3%)
$230.40
(+27%)
Bear:
(PE: 16.9, Growth: 8.3%)
$195.84
(+8%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (38x PE), but valuation improves significantly next year (20x PE) as earnings recover.
Trailing PE: 37.57 | Current EPS (TTM): $5.04
Bull Case
$376.36
(+98%)
Analyst growth 80.7%, PE expands to 41.3
Base Case
$342.14
(+80%)
Market implied 80.7%, PE stable at 37.6
Bear Case
$128.76
(-32%)
Severe decline -20.0%, PE contracts to 31.9
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 19.9 to 24.9
Stabilization Target:
$226.76
(+24.9%)
PE Expansion Potential:
+24.9%
Share & Embed Analysis
Last updated: March 30, 2026 3:07 PM ET
Data refreshes hourly during market hours. Next update: 4:07 PM
Data refreshes hourly during market hours. Next update: 4:07 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is DHR showing a specific setup today?
Insider Activity (6 Months)
3
Buys
11
Sells
Net
INSIDERS SELLING
Recent Transactions
Ro Khanna
SELL
2026-02-24
Gregory M Milosevich
SELL
1320 shares
2026-02-19
Ro Khanna
SELL
2026-02-18
Featured in Portfolios
DHR is a key holding in these high-performance investment strategies.
Top Rated Diagnostics & Research Stocks
Top-rated stocks in Diagnostics & Research by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
TMO
Thermo Fisher Scientific… |
STRONG BUY
31 analysts |
$664 | 60 BUY |
|
EXAS
EXACT Sciences Corporati… |
STRONG BUY
26 analysts |
$106 | 65 BUY |
|
GH
Guardant Health Inc |
STRONG BUY
24 analysts |
$133 | 56 HOLD |
|
NTRA
Natera Inc |
STRONG BUY
21 analysts |
$261 | 54 HOLD |
|
IQV
IQVIA Holdings Inc |
BUY
23 analysts |
$236 | 61 BUY |
Advanced DHR Option Strategies
Professional options setups generated by AI based on today's DHR price and gamma walls.
